Cardinal Health (NYSE:CAH)‘s stock had its “hold” rating reiterated by investment analysts at Mizuho in a research report issued to clients and investors on Sunday. They currently have a $53.00 target price on the stock. Mizuho’s price target indicates a potential upside of 9.19% from the company’s current price.
CAH has been the topic of several other research reports. ValuEngine downgraded Cardinal Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised Cardinal Health from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Monday, April 16th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $56.00 target price on shares of Cardinal Health in a research report on Tuesday, August 7th. Leerink Swann set a $65.00 target price on Cardinal Health and gave the company a “buy” rating in a research report on Saturday, May 5th. Finally, Argus lowered their target price on Cardinal Health from $85.00 to $75.00 and set a “buy” rating on the stock in a research report on Monday, July 16th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $62.00.
Shares of CAH traded up $0.14 during midday trading on Friday, hitting $48.54. The stock had a trading volume of 9,876 shares, compared to its average volume of 4,143,857. Cardinal Health has a twelve month low of $48.14 and a twelve month high of $75.75. The company has a market capitalization of $15.04 billion, a price-to-earnings ratio of 9.74, a P/E/G ratio of 1.78 and a beta of 0.99. The company has a debt-to-equity ratio of 1.32, a current ratio of 1.07 and a quick ratio of 0.54.
Cardinal Health (NYSE:CAH) last released its quarterly earnings results on Monday, August 6th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.93 by $0.08. Cardinal Health had a return on equity of 22.59% and a net margin of 0.19%. The firm had revenue of $35.35 billion for the quarter, compared to the consensus estimate of $34.38 billion. During the same quarter last year, the business posted $1.31 EPS. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. sell-side analysts anticipate that Cardinal Health will post 5.04 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC acquired a new position in Cardinal Health during the first quarter worth approximately $100,000. Optimum Investment Advisors acquired a new position in Cardinal Health during the first quarter worth approximately $128,000. Sentry Investment Management LLC acquired a new position in Cardinal Health during the second quarter worth approximately $132,000. Mount Yale Investment Advisors LLC acquired a new position in Cardinal Health during the first quarter worth approximately $136,000. Finally, Focused Wealth Management Inc acquired a new position in Cardinal Health during the first quarter worth approximately $166,000. 89.98% of the stock is currently owned by institutional investors and hedge funds.
About Cardinal Health
Cardinal Health, Inc operates as an integrated healthcare services and products company worldwide. The company's Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare, and consumer products to retailers, hospitals, and other healthcare providers.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.